title: [Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].
abstract: Lung cancer is the leading cause of cancer death worldwide, and it is responsible for 20-25% of all cancer deaths. In Hungary, more than 4,000 lung cancer patients receive chemotherapy every year, and of them 3,000 suffer from non-small cell lung cancer. Despite the rapid development in antitumor treatment options, the response rates of chemotherapies in non-small cell lung cancer still remain between 15-35%. Recently, EGFR tyrosine kinase inhibitor therapy has been introduced with a response rate of 15% when used in unselected patients. However, this ratio may increase up to 70% when only patients with tumors containing EGFR mutation are treated. Therefore, results of translational research that could help pulmonologists and oncologists to apply tailored therapy in lung cancer patients are of great importance. The purpose of our work was to establish a model in order to study the relevance of immunohistochemical and molecular biological analyses of tumor specimens in treatment and patient selection, and to investigate their cost-sparing effects. We concluded that the most cost-effective type of patient selection could be achieved with EGFR mutation status analysis of the tumor tissue. Our results may help to determine the most cost-effective way of patient selection in case of non-small cell lung cancer patients requiring second line therapy; moreover, they might serve as a basis for further economic analyses.
authors.affiliation: Pulmonológiai Klinika, Semmelweis Egyetem, Budapest, Hungary. drmoldvay@hotmail.com
authors.forename: Judit
authors.initials: J
authors.lastname: Moldvay
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D006801:Humans; D006814:Hungary; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000191:economics*; D009154:Mutation; D018579:Patient Selection; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000627:therapeutic use; D011799:Quinazolines / Q000191:economics / Q000627:therapeutic use; D018631:ras Proteins / Q000032:analysis / Q000187:drug effects / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D018631:ras Proteins